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Abstract
Surgical resection of the primary tumor may enhance the metastasis 
and recurrence of cancer. The reaction of patients to surgery includes 
changes of the immune system, the inflammatory system and the neu-
roendocrine system. In the perioperative period, anesthetics are used 
both for anesthesia and analgesia. There are several studies showing 
that the progression of cancer can be influenced by many kinds of 
anesthetics, although most of these studies are preclinical and thus 
have not yet influenced clinical recommendations. This review sum-
marizes recent studies regarding the effects of anesthetics on metasta-
sis and recurrence of cancer.
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Introduction
For many cancers, surgical resection of the primary tumor 
is the mainstay of treatment; however, there is increasing 
evidence that this may actually promote the recurrence and 
metastasis of cancer. Whether this occurs depends largely on 
the tumor’s ability to spread combined with the host immu-
nity and inflammatory response [1]. There are many factors 
that impact on this perioperatively, such as surgical stress, 
blood transfusions, hypothermia, hyperglycemia, and postop-
erative pain. The immune system is suppressed by surgery, 
which promotes inflammation. Additionally, the endocrine 
system diminishes host tumor response. All these periopera-
tive changes offer a favorable microenvironment, promoting 
residual and circulating cancer cells to proliferate and metas-
tasize after operation [2]. Undergoing surgery thus creates 
the “perfect storm” [3], throughout which the judicious and 
careful selection of anesthetic and analgesia is vital, not only 
for safety purpose during the “storm”, but also for optimal 
postoperative outcomes.
This has then raised the question of what impact the 
anesthesia itself has on this perioperative tumor promoting 
environment. Studies focus on four main fields: the effect on 
immune system, the effect on inflammatory system, the ef-
fect on the microenvironment and the direct effect on cancer 
cells. This review collates the evidence regarding anesthetic 
effects on metastasis and recurrence of cancer (Table 1) [4-
17].
The Effect of Surgery on the Progression of 
Cancer
Surgery presents opportunities not only for eradicating tumors, 
but also for proliferation and invasion of residual cancer cells. 
Surgery increases the shedding of malignant cells into the 
blood and lymphatic circulations, inhibits their apoptosis and 
potentiates their invasion capacity [18]. Surgery also increases 
the factors related to tumor vascularity and levels of growth 
factors, endorsing local and distant recurrence. The immune 
system, the inflammatory system and the neuroendocrine sys-
tem react to surgery with notable changes which have been 
proven to promote progression of cancer [19]. Psychological 
distress (anxiety, stress and depression) initiated by surgery, 
releases stress hormones and down-regulates cellular immune 
indices [20].
A successful metastasis of cancer cells is determined by 
their microenvironment. For example, without periostin which 
is released locally by fibroblasts within the tumor microen-
vironment, metastasizing breast cancer stem cells are unable 
to deposit in lung models [21]. In colorectal cancer, hepato-
cyte growth factor (HGF) secreted by myofibroblasts induces 
epithelial-mesenchymal transition (EMT) which is known to 
play a pivotal role in mediating invasion and metastasis [22]. 
The inflammatory mediators induced by pro-inflammatory cy-
tokines (TNF-α, IL-1β and IL-6), instigate and facilitate cross 
talk at the cancer cell-stromal interface. This promotes metas-
tasis of tumor cells through initiation of metastatic coloniza-
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tion, acting somewhat as a “fertilizer” to aid successful tumor 
growth [22].
Specific factors initiated by surgical trauma can influence 
the progression of cancer, including catecholamines, prosta-
glandins, glucocorticoids, various cytokines, pro-angiogenic 
factors, opioids, etc. [18]. Growth factors such as vascular en-
dothelial growth factor (VEGF) and EGF, elevated by surgery, 
are demonstrated to potentiate the metastatic ability of cancer 
stem cells [23]. Many studies have particularly reported on the 
enhancement of catecholamines and prostaglandins on cancer 
development, both by immunosuppression and by direct facili-
tation of malignant tissue progression and the interventions to 
decrease the levels of these factors for a better prognosis have 
been taken on in clinical studies, as will be discussed in the 
following sections.
The Effect of Volatile Agents on Cancer
The anesthetic mechanism of volatile agents is complicated, 
targeting a number of sites including GABA receptors and 
NMDA receptors [3]. Studies in vitro and in vivo have shown 
that there is an association between inhalational anesthesia and 
increased tumor spread [4, 24]. In a recent retrospective study, 
it was found that cancer patients had a worse survival outcome 
if they received inhalational anesthesia [25]. Inhalational anes-
thesia inhibits the immune system by decreasing the function of 
natural killer cells, which play an important role in protecting 
against proliferation of cancer cells [26]. It was reported that 
isoflurane could promote the growth and migration of glioblas-
toma cells [5], up-regulate levels of hypoxia-inducible factor 
(HIF)-1α and HIF-2α and intensified expression of VEGF A 
[27]. HIF-1α is overexpressed in a variety of carcinomas and 
their metastases, and is deemed to be a transcriptional regula-
tor of VEGF expression, mediating angiogenic responses [28, 
29].
On the contrary, sevoflurane was found to attenuate VEGF 
level via DNA methylation [30]. Sevoflurane had a dose-de-
pendent inhibition of glioma cells, not only by increasing the 
expression of miRNA637 and decreasing the expression of 
Akt1 and phosphorylated Akt1 [31], but also by inhibiting 
MMP-2 activity [6]. Liang et al found the invasion of lung 
cancer cells induced by platelets could be suppressed by sevo-
flurane via decreasing platelet activity [32]. Combined with 6 
MV photon, sevoflurane down-regulated cdc42 overexpres-
sion and decreased the migration speed of human adenocarci-
noma cell line A549, potentially providing clinical benefit for 
the cancer therapy [33]. However, Sugimoto et al have a con-
trary conclusion that sevoflurane enhances colon cancer cell 
line proliferation via K (ATP) channels in cancer cells [34]. 
Elias et al studied 194 women with stage III epithelial ovar-
ian cancer undergoing optimal primary cytoreduction. They 
concluded that compared with sevoflurane, the use of desflu-
rane was associated with a lower overall rate of ovarian can-
cer recurrence, and desflurane was independently associated 
with an improved disease-free survival [7]. As we know, there 
are a number of factors that need to be taken into account 
when interpreting these retrospective studies and prospective 
randomized controlled trials should be taken to verify these 
conclusions.
The Effect of Intravenous Agents on Cancers
Propofol
As a short-acting intravenous anesthetic agent, propofol is 
widely used for sedation and hypnosis during and after op-
eration. It exerts anesthesia by activating GABA A receptors 
directly, to slow the channel-closing time and by blocking 
sodium channels [35]. A retrospective analysis compared 
propofol with sevoflurane and found the 1-year survival af-
ter colon cancer operation in the propofol group was almost 
10% higher [36]. Ji et al concluded that propofol-based total 
intravenous anesthesia (TIVA) for breast cancer surgery can 
reduce the risk of recurrence during the initial 5 years after 
modified radical mastectomy [37]. Propofol is supposed to 
protect the immune system from being inhibited periopera-
tively [35, 38, 39] and have a lower inflammatory response 
than volatile agents [40-42]. An in vivo study assessed propo-
fol’s effect on pulmonary cancer metastasis [43]. After ad-
ministration of propofol or saline intravenously, 40 rats were 
injected with pulmonary cancer cells. Three weeks later, it 
was found the doses of propofol were inversely correlated 
with the number of pulmonary metastasis. Similarly, propo-
fol drastically inhibited hepatocellular tumor growth in rat 
models [44].
Some studies in vitro focus on the direct effects of propofol 
on cancer cells. It can be concluded that propofol can induce 
apoptosis and inhibit the growth of cancer cells by activating 
different signal pathways. Deng et al found propofol inhibits 
migration of colorectal cancer cell (CRC), both in vitro and in 
vivo by activating (PI3K)/AKT signaling and inducing EMT 
[8]. Through downregulation of TGF-β1 expression, propofol 
effectively inhibits proliferation and invasion and induces apo-
ptosis of osteosarcoma cells [9]. Liu et al concluded propofol 
inhibits invasion and induces apoptosis of pancreatic cancer 
(PANC-1) cells by regulating MicroRNA (miR) -21/Slug sig-
nals [10]. Only one study has found the opposing conclusion 
that propofol induces proliferation and invasion of gallbladder 
cancer cells [45].
Etomidate
Etomidate has minimal effects on hemodynamics, and is thus 
considered for use particularly in older or critically ill, hemo-
dynamically unstable patients. With respect to its inhibition 
of adrenal cortex function, etomidate is not recommended for 
immunosuppressed or septic patients. Very few studies have 
investigated the effect of etomidate on cancer. In one study 
in vivo, etomidate was found to reduce the viability of mac-
rophages significantly, in a dose-dependent manner [46]. In a 
clinical study, they found etomidate had less effect on immune 
function in patients with lung adenocarcinoma than propofol 
[47].
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Alpha2-adrenoceptor agonists
Dexmedetomidine (DEX) is a highly selective α2-adrenergic 
receptor agonist, used increasingly in operations for seda-
tive, anxiolytic, and analgesic purposes. It was found that 
α2-adrenoceptors are expressed in human breast cancer cell 
lines, and activation of these receptors was associated with 
an enhancement of cell proliferation [48]. An in vivo murine 
study confirmed this conclusion [49]. In mice treated with 
DEX, there was a significant increase in tumor growth and 
metastasis, which was associated with an alteration in mam-
mary tumor collagen microstructure [50]. Xia et al found DEX 
could promote the growth of established breast tumors in vivo 
through the activation of α2β-adrenoceptor/ERK signaling 
[51]. However, a different study found DEX had minimal ef-
fect on the migration of CRCs [8].
Opioids
Opioid drugs are widely used to manage pain during and af-
ter operation. A retrospective analysis suggested an associa-
tion between increased doses of opioids during the initial 96 
h postoperative period, with a higher recurrence rate of non-
small-cell lung cancer within 5 years [52]. Intraoperative opi-
oid use is associated with decreased overall survival of non-
small cell lung cancer (NSCLC) patients [11]. Similarly Forget 
et al found that intraoperative sufentanil administration was 
related to an increased risk of cancer recurrence after radical 
prostatectomy [53]. However, in a clinical trial, there were no 
differences in immunosuppression and recurrence between the 
opioid group and the ropivacaine group [54]. The limitation in 
this study was the short follow-up period of 12 months, and the 
immune function was assessed only by NK cell cytotoxicity 
(NKCC) and interleukin (IL)-2, not including T-helper cells 
and cytotoxic T cells.
It has been proved that opioid receptors exist not only in 
neurons but also in immune cells (granulocytes, monocytes/
macrophages, lymphocytes, and natural killer cells) [55] and 
tumor cells originating from glioma and colon, breast, lung, 
pancreatic, thyroid, endocrine and endometrial cancers. The 
expression of μ opioid receptors (MOR) in human lung cancer 
is significantly increased compared with adjacent control tis-
sue (P = 0.0242) and is nearly two-fold higher in those with 
metastatic lung cancer in comparison to non-metastatic disease 
[56].
By stimulating these receptors, opioids exert their ef-
fects on tumors in myriad ways [57], which has both direct 
effect on the proliferation and invasion of tumor cells [58] 
and indirect effects on the tumor including immunosuppres-
sion, pro-inflammation and pro-angiogenesis [59]. An in vitro 
study showed morphine, an MOR activator, decreased tumor 
multiplication, and intermittent injections inhibited the pro-
liferation of adenocarcinoma cells [60]. Afsharimani et al 
found morphine exerts anti-tumor effects through modulation 
of paracrine communication between cancer cells and non-
malignant cells in the tumor microenvironment [61]. A recent 
study found morphine promotes renal cell carcinoma growth 
and progression via over-expression of surviving [12]. Tumor 
development is often accompanied and enhanced by an inflam-
matory response. It has been pointed out that different types of 
opioid receptors have conflicting effects on inflammation and 
activating MOR induces a pro-inflammatory response which 
could enhance tumor development [62].
In addition, continuous administration of high doses of 
morphine is more likely to inhibit tumor growth and metasta-
sis in rodent models. In contrast, intermittent injection induces 
withdrawal-like conditions and activates the hypothalamic-
pituitary-adrenal (HPA) axis which is known to facilitate can-
cer progression and metastasis [63]. So not only is the type of 
opioid receptor potentially important, but the method of dos-
ing may influence whether opiate analgesia has a pro- or anti-
tumor effect.
Ketamine
In a model of breast cancer metastasis, rats were anesthetized 
for 1 h with ketamine, thiopental, halothane, or propofol, and 
then injected IV with MADB106 tumor cells [26]. The num-
ber and activity of circulating NK cells after anesthesia and 
lung tumor retention 24 h later was assessed. Lung metastases 
were counted 3 weeks later. The author found ketamine caused 
a significant decrease in NK cells, and increased lung tumor 
retention and lung metastases most potently. This effect was 
markedly reduced in rats pre-treated with the beta blocker nad-
olol, or with chronic small doses of an immunostimulator. The 
authors suggest NK activity was suppressed by ketamine and 
this promoted MADB106 metastasis. He et al found ketamine 
can up-regulate the level of anti-apoptosis protein Bcl-2 and 
promotes breast cancer cell invasion and proliferation [64].
In contrast, in a recent study, ketamine was seen to inhibit 
pancreatic cancer cell proliferation and apoptosis as an N-me-
thyl-D-aspartate (NMDA) antagonist [65]. It can be seen that 
ketamine has a pro-tumor effect by inhibition of immune func-
tions, whereas its direct effect on cancer cells is still debatable.
Non-steroidal anti-inflammatory drugs (NSAIDs)
Inflammation plays an important role in cancer. Long-term ad-
ministration of NSAIDs has shown to decrease the incidence, 
recurrence and proliferation of various cancers, such as colon, 
breast, lung, and pancreatic cancer [66]. But only a few studies 
have focused on the effect of perioperative use of NSAIDs. A 
retrospective study indicated that perioperative administration 
of ketorolac for lung cancer patients was marginally associated 
with better overall survival (P = 0.05) [67]. Forget et al found 
NSAIDs used at the beginning of the surgery is independently 
associated with a lower metastases risk after lung cancer sur-
gery and ketorolac use is independently associated with longer 
survival [68]. Ketorolac given before surgery was also found 
to have a lower cancer recurrence rate [69]. In an in vivo mu-
rine model of tumor metastasis, there was no difference be-
tween continuous or perioperative treatment with celecoxib, a 
selective cyclooxygenase 2 inhibitor, as both modes of admin-
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istration decreased lung metastases significantly [70].
The Effects of Local Anesthetics on Cancers
Local anesthetics exert their effect by blocking voltage-gated 
sodium channels (VGSC) on the nerve cell membrane, which 
are also found on tumor cell membrane and are thought to be 
correlated with the invasion and metastasis of tumor cells [71]. 
Recent studies have focused on the anti-tumor properties of 
local anesthetics. Wang et al investigated the influence of local 
anesthetics on NSCLC cells, and found lidocaine and ropiva-
caine can inhibit the growth, invasion and migration of can-
cer cells, as well as induce their apoptosis [13]. The authors 
suggest the local anesthetics activate the mitogen-activated 
protein kinase (MAPK) pathway, caspases Bcl-2 and the in-
trinsic mitochondrial apoptosis pathway. Similar results can be 
found in the study of lung adenocarcinoma cells from Piegeler 
et al [14] and the study of breast cancer from Lirk et al [72], 
although the supposed mechanisms in these studies were dif-
ferent. In a very recent study, researchers applied lidocaine to 
human hepatocellular carcinoma cells in vitro and also in a 
xenograft model, and certified the anti-tumor effect of lido-
caine [15]. In addition, lidocaine is supposed to sensitize breast 
cancer cells to the cytotoxicity of cisplatin [73] and have an 
effect on reversing cancer multidrug resistance [74].
The anti-tumor properties of local anesthetics offer a po-
tential opportunity for clinical application. Intravenous use 
of lidocaine has been shown to possess an anti-inflammatory 
property [75]. In a prospective study, patients undergoing radi-
cal hysterectomy were given continuous infusion of lidocaine 
or the same volume of normal saline as control during opera-
tion [16]. The author found lidocaine treatment attenuated the 
early apoptosis of lymphocytes and preserved the ratio of in-
terferon gamma to IL-4, which means lidocaine exerts a pro-
tective effect on cell-mediated immunity and may be beneficial 
in inhibiting tumor recurrence.
Conclusion
Taken together, when compared with other types of anesthet-
ics, inhalation agents do not appear to be superior to intra-
venous agents in cancer operations. Isoflurane can enhance 
proliferation and metastasis of cancer cells in vitro and rodent, 
while sevoflurane seems to possess an anti-tumor property in 
most studies. Most of current studies agree that propofol pos-
sesses an anti-tumor property including immune-modulation, 
anti-inflammation and inhibition of cancer cells proliferation 
and invasion. NSAIDs possess an anti-tumor quality which is 
confirmed by clinical studies. The perioperative (short term) 
use of NSAIDs seems to have a similar effect, which needs 
prospective clinical studies. Opioid seems to have paradoxi-
cal effects on tumors, due to combinations of intricate mecha-
nisms, including inhibition of cancer cells proliferation, im-
munosuppression, pro-inflammation and alleviation of pain 
and stress. In addition, types of tumor, different doses and 
patterns of administration may result in inverse responses. 
Amide-linked local anesthetics may have anti-tumor proper-
ties.
Thus, anesthetic selection may well influence the progno-
sis of cancer patients. However, studies in vitro and in animal 
models are not always truly reflective of the human clinical 
position. Until now, most of the clinical studies are retrospec-
tive, and some of them are contradictory. With no official 
consensus, the effect of anesthetics and analgesics on cancer 
requires further study, particularly with regards to prospective 
randomized controlled trials.
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